New York City Faces a Rising Threat from a Superbug
Move over, bed bugs and roaches. New York City is now grappling with a “superbug” that’s proving tough to eliminate.
Candida auris, for instance, clings to surfaces even after thorough cleaning. It frequently evades standard antifungal treatments and can lead to serious bloodstream infections, which can be fatal.
Since New York state first identified this dangerous fungus in 2016, reported cases have been on the rise. For example, there were 623 clinical cases last year—people who actually fell ill—and another 849 surveillance cases, where individuals tested positive but did not show symptoms.
Recent studies suggest that the New York City/New Jersey area is responsible for about 20% of all Candida auris infections in the country. Experts believe that heavy travel and trade with South Asia have contributed to this increase.
But Candida auris isn’t the only alarming superbug wreaking havoc in the city. Health specialists are cautioning that the overprescription of antibiotics is leading to a rise in “nightmare bacteria,” which have developed resistance to many treatments.
Dr. Aaron Glatt, a medical professor, pointed out that using antibiotics for viral illnesses, like common colds, is ineffective. This can cause more harm, not just in side effects but also in fostering antibiotic resistance.
Antibiotics should be reserved for treating bacterial infections such as strep throat and urinary tract infections, not for viral conditions like colds or flu, where they offer no benefit and contribute to resistance.
The emergence of antibiotic-resistant bacteria is largely due to natural genetic changes, allowing these resistant strains to spread their traits to other bacteria.
In fact, the World Health Organization noted last fall that one in six bacterial infections was resistant to commonly used antibiotics. They reported an increase in resistance rates of 5% to 15% annually from 2018 to 2023.
This issue worsened during the COVID-19 pandemic, as many patients with mild coronavirus infections were unnecessarily prescribed antibiotics.
“It’s a mix of situations where patients get antibiotics when they don’t need them, plus it’s on doctors to clarify when antibiotics aren’t the solution,” Glatt said.
On a more positive note, although Candida auris is widespread in New York, it mainly affects individuals in medical settings such as hospitals and nursing homes rather than the general public.
According to Glatt, “For most people living normally, this isn’t a huge worry. However, it’s a grave concern for those in nursing homes, or for patients who have taken multiple antibiotics and are critically ill or immunocompromised.”
In promising developments, a new drug has shown effectiveness against resistant bacteria like E. coli and Klebsiella pneumoniae.
There’s also federal bipartisan legislation aimed at addressing this crisis. Originally proposed in 2020 and reintroduced recently, the Pasteur Act seeks to enhance the antibiotic pipeline, making sure we can better combat these formidable bacteria.
This groundbreaking act proposes a subscription model to fund new antibiotics, meaning drug companies would receive set payments based on the value of their innovations rather than sales volume. The idea is to stabilize the market and spur more research.
Glatt explained, “This Netflix-style model means the government will pay for access to these antibiotics at a flat rate, regardless of usage. This ensures that pharmaceutical companies are fairly compensated for their research while keeping prices manageable.”
